Background: Gas6 protein is involved in pulmonary embolism (PE) and acute inflammation in animal models. Methods: We enrolled 82 consecutive patients with acute dyspnea and suspected PE (Geneva score with high (HCP) or low/intermediate clinical probability (LICP) þ D-dimer !0.5 mg/mL) and 29 age-matched healthy volunteers. According to clinical and instrumental evaluations the following diagnoses were obtained: heart failure (HF), pulmonary or systemic infection (I), PE, or no illness (N). Twenty-two patients were excluded due to oral anticoagulation (9), lack of CT angiography or pulmonary scintigraphy (6), plasma creatinine !3 mg/dL (3), and pulmonary cancer (4). Plasma Gas6 was measured with a validated enzyme-linked immunoassay. Non-parametric tests and accuracy measures were calculated. Conclusions: The data link Gas6 protein to infection/inflammation, but not to PE, in humans. Gas6 assay was useful in PE diagnosis, improving D-dimer accuracy particularly in LICP patients, and limiting false positives. ª
Introduction
The differential diagnosis of acute dyspnea is often challenging because it is difficult to identify the underlying disease rapidly. Only a few biomarkers are reliable;
1 even more so in relation to pulmonary embolism (PE), in which the only reliable plasma marker is D-dimer.
2 Gas6 (growtharrest-specific protein 6) is a 75-kDa protein with 44% homology to coagulation protein S. 3, 4 Both proteins bind to tyrosine kinase Tyro3 family receptors (Axl, Tyro-3, Mer) but Gas6 has greater affinity for Axl. 5e8 These receptors have been found to be coexpressed with Gas6 protein in CNS, endothelium, platelets and monocytes. 9e12 There is evidence to support Gas6 protein involvement in the pathogenesis of PE: gas6 À/À mice are protected from induced venous thromboembolism because they develop smaller and fewer organized intravascular thrombi comparing to wild-type animals. Mice treated with antiGas6 antibodies display the same phenotype, and are equally protected against fatal thromboembolism.
12,13
Other reports indicate a possible role for Gas6 protein in control of innate immunity and in inflammation processes. Axl À/À, Mer À/À and Tyro 3 À/À mice display hyperactivation of monocytes/macrophages with a higher susceptibility to endotoxic shock and consequent mortality; their monocytes react with an excessive secretion of tumor necrosis factor (TNF)-a and interleukin (IL)-6 after lipopolysaccharides (LPS) challenge. 14, 15 Some authors have also suggested the potential involvement of Gas6 in acute inflammation in humans because plasma Gas6 concentrations were found to be significantly increased in patients affected by septic shock in intensive care units. 16, 17 Data relating to the plasma concentration of Gas6 in humans with PE are not available.
PE and pulmonary or systemic infections are common causes of acute dyspnea. We tried to evaluate if plasma Gas6 concentration varied among different causes of acute dyspnea; this could aid differential diagnosis in patients with acute dyspnea and suspected PE.
Methods Patients
From March 2005 to August 2008 we enrolled 82 consecutive patients with acute dyspnea due to suspected PE in the present observational study. Inclusion criteria were: acute dyspnea onset within the last 24 h and one of two findings: (1) Geneva 18 score !9 (high clinical probability for PEdHCP); or (2) Geneva score <9 (low/intermediate clinical probability for PEdLICP) together with plasma D-dimer value !0.5 mg/mL. Patients were aged >18 years and gave written informed consent. At the beginning of the enrollment a review board was not required for observational studies. Patients were excluded if plasma creatinine was !3 mg/dL, if they suffered from a primitive or secondary pulmonary cancer, or if they were being treated with oral warfarin.
All patients included were evaluated for PE diagnosis according to in-use medical practice with either thorax contrast-enhanced multidetector spiral computed tomography (CT angiography) or with pulmonary perfusion scintigraphy (111 MBq of 99m Tc-MAA mean dose). At enrollment, before any imaging exam, a 20-mL blood sample was drawn from enrolled patients. Plasma and serum samples were obtained within 1 h after centrifugation and stored at À80 C. Gas6 was measured at the end of the enrollment. 
PE
Pulmonary embolism Positive CT angiography of thorax or scintigraphy lung perfusion with high probability for PE confirmed by significant improvement or resolution of PE after at least 7 days of anticoagulation with low molecular weight heparin or oral warfarin Clinical data and the other instrumental examination results were used to classify patients into one of four groups: absence of acute cardiopulmonary illness (for example anxiety) (N), acute heart failure (HF), pulmonary or systemic infection including chronic obstructive pulmonary disease (COPD) exacerbations (I), and pulmonary embolism (PE). The definitions and diagnostic criteria used for these groups are described in Table 1 . Patients with a combination of causes of dyspnea (e.g. COPD exacerbation and acute heart failure) were not considered. Two physicians defined all the diagnoses independently. Discordant diagnoses were revaluated and assigned by consensus.
A group of 29 volunteers age-matched to patients were enrolled if they were healthy, except for arterial hypertension under treatment. Healthy controls had 20 mL of blood taken, and samples processed as described above.
Laboratory analysis
Blood gas data, without oxygen supplementation, and plasma creatinine were assayed in automated laboratory equipment (ADVIA 1650, Bayer Diagnostics Italia). D-dimer was assayed with VIDAS D-dimer enzyme-linked fluorescent assay on an automated immunoassay system (bioMérieux Italia).
Gas6 protein was measured with a sandwich enzymelinked immunoassay (ELISA). The method has been validated according to Food and Drug Administration (FDA) guidelines 19 in a previous study (inter-assay and intra-assay %CVs were within 15%, mean recovery on 15 patients of 96%, lower limit of quantificationdLLOQd0.25 ng/mL). 20 Briefly, a 96-well plate (NUNC ImmunoPlates, UK) was coated overnight with anti-Gas6 primary antibody (Goat polyclonal affinity purified IgG, R&D Systems, Minneapolis, USA). Antigen was detected by a secondary biotin-conjugated antibody (Biotinylated anti-human Gas6 antibody, R&D Systems, USA) and a streptavidineperoxidase conjugate (Sigma, USA) and TMB (3, 3 0 ,5,5 0 -tetramethylbenzidine, Sigma, USA). The reaction was blocked with 1.8 M sulfuric acid; absorbance was detected at 450 nm with a reference wavelength set at 570 nm. Optical density was fitted versus nominal concentration, applying a four-parameter logistic regression to the calibration curve prepared in Gas6-depleted human plasma with human recombinant Gas6 addition (R&D, USA). 20 
Statistical analysis

Results
Out of the 82 patients enrolled, 60 were included; 8 were N, 12 had HF, 11 had I, and 29 had PE. Of the 22 excluded, 9 patients were already being treated with anticoagulation (p.o.), 6 patients lacked a CT angiography or evidence of PE resolution with pulmonary scintigraphy, 3 patients had plasma creatinine >3 mg/dL, and 4 patients suffered from a primitive pulmonary cancer. All patients included displayed D-dimer values higher than 0.5 mg/mL. All variables analyzed did not have a normal distribution in any diagnostic group (ShapiroeWilk, p > 0.05).
Gas6 median concentration was equivalent in the N and healthy volunteers groups (20.4 ng/mL (17.6e21.6) and 19.1 (17.2e21.4) respectively) (ManneWhitney U-test, p Z not significant (n.s.)). Gender did not influence Gas6 concentration within each group in healthy controls (ManneWhitney U-test, p Z n.s.). Table 2 details patients' characteristics; there were no significant differences in age and plasma creatinine concentration among groups (KruskaleWallis variance, p > 0.1). Table 2 and Figure 1 also report median plasma Gas6 concentration of each group. In non-parametric posthoc comparisons, median plasma Gas6 concentration in HF group or I group patients was higher than in those of PE or N groups (KruskaleWallis test for multiple comparisons, N vs. HF p Z 0.05, N vs. I p < 0.002, I vs. PE p < 0.0001, I vs. N p < 0.002). Plasma Gas6 concentration was also higher in the I group than the HF group though it was not significant, and was nearly identical compared to PE and N groups (ManneWhitney U-test, p Z 0.9).
We evaluated the usefulness of Gas6 as a diagnostic test for PE. D-dimer 0.5 mg/mL determined a 52% [95% CI 39e65] false positive rate. Gas6 testing on D-dimer positive subjects displayed high true positive and low false positive rates for several cut-offs tested with a greater performance in patients with LICP for PE (Geneva score <9) (Table 3) . Moreover, as shown in receiver operator characteristics curve analysis of Figure 2 , area under the curve (AUC) of Gas6 in PE diagnosis was 0.80 for all patients and 0.91 for (Table 4) .
Discussion
Since gas6 is involved in PE or systemic inflammation in animals, 12e15 we evaluated plasma Gas6 protein concentration in humans in relation to different causes of acute dyspnea.
We measured a median concentration of 19.1 ng/mL in healthy volunteers, which was nearly identical to that observed in young healthy donors in a previous study. 20 A group from Sweden obtained very similar results applying a different ELISA method. 21 Researchers from France obtained a Gas6 concentration of 52.0 ng/mL and 63.8 ng/ mL in healthy men and women, respectively. 22 Although we cannot exclude ethnic or geographical variations, we suggest that differences in assay methods could explain this discrepancy.
Our results demonstrated that a Gas6 protein test could be useful for the differential diagnosis of acute dyspnea:
Gas6 assay substantially increased D-dimer predictive value in defining PE diagnosis. This effect was even more apparent in patients with low to intermediate clinical probability for PE. This fact is important since the patients with loweintermediate probability for PE display a higher proportion of false positivity on the D-dimer test. Therefore these two tests used in combination could more accurately identify PE, helping the clinician to avoid further expensive instrumental work-up (pulmonary scintigraphy or CT angiography).
Plasma Gas6 concentration was increased by about two times the normal value in patients with acute dyspnea due to pulmonary or systemic infection. This finding confirms the hypothesis that Gas6 protein may be involved in acute inflammation: a monocyteemacrophage hyperactivation has been described in mice lacking Gas6 receptors 14, 15 and plasma Gas6 concentration increases in patients with severe sepsis, proportionally to disease severity. 16, 17 Thus Gas6 seems to be involved in macrophage function, being a possible biomarker of this activity.
We also demonstrated a 1.5-fold increase in plasma Gas6 concentration in subjects suffering from acute HF with respect to baseline values. The elevation of inflammation biomarkers and in particular of cytokines involved in innate immunity, such as TNF-a, in HF is well documented. Gas6 elevation may be interpreted as an indicator of innate immunity activation in this setting.
Gas6 protein was found to be expressed in mouse platelets, secreted after platelet activation and bound to Gas6 receptors on the platelet surface, suggesting an autocrine stimulatory mechanism; moreover gas6 À/À mice were protected from fatal thromboembolism similar to wild-type mice treated with anti-Gas6 antibodies, without alteration in bleeding. 12, 13 Platelet aggregates of Gas6 À/À mice are loosely packed with few contact sites, and are incompletely degranulated. 26 All these data suggest that Gas6 interaction with its receptors is important in thrombus stabilization, possibly through an outside-in signaling involving the integrin a IIb b 3 ; however the interaction of Gas6 with its receptors is involved only in amplifying the response of other platelet agonists but not determining platelet activation by itself, as is true for other molecules such as Eph kinases and ephrins or CD40 ligand. 26 Additionally, Gas6 binds to its receptors through a domain that needs a vitamin K dependent g-carboxylation to be active, tightly linking this protein to hemostatic processes. 27 In contrast to the evidences exposed above, we found that PE does not influence plasma Gas6 concentration in humans. The simplest explanation for this discrepancy is that Gas6 may be important for thrombus formation but it is not overexpressed or released during platelet aggregation or during the coagulation process, perhaps acting as a membrane protein for platelets or endothelial cells. 12, 13 It should also be considered that other authors have raised concerns about Gas6 function in human hemostasis: they failed to find Gas6 protein expression in human platelets, suggesting that it may not be as relevant in humans as it is in mice. 21 Our data seem to support the latter hypothesis; however, further research is needed to clarify Gas6 function in human hemostasis.
In conclusion, plasma Gas6 concentration is increased in patients with acute dyspnea due to HF and even more in patients with systemic or pulmonary infection; Gas6 concentration in PE is unaffected. These data confirm the hypothesis that Gas6 protein is involved in inflammation and in particular in activation of innate immunity. Gas6 testing considerably improved the accuracy of the D-dimer test in PE diagnosis, limiting false positives. However, the clinical utility of plasma Gas6 detection in the differential diagnosis of acute dyspnea in PE evaluation must be confirmed in a larger study. 
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